血清CA125和IL-10水平测定在评估晚期非小细胞肺癌患者预后中的价值

摘要

目的 探讨血清CA125和IL-10水平测定在评估晚期非小细胞肺癌(NSCLC)患者预后中的价值.方法 本文对132例晚期NSCLC患者进行了治疗前后血清CA125和IL-10水平的测定,并与76例良性肺部疾病患者进行了比较性分析,采用受试者工作特征曲线(ROC曲线)分析了CA125和IL-10水平在评估晚期NSCLC患者预后中的价值.结果 132例晚期NSCLC患者(包括51例腺癌、53例鳞癌和28例腺鳞癌)血清CA125和IL-10水平较76例良性肺部疾病患者明显增高(P<0.05~0.001).Ⅳ期和低分化NSCLC患者血清CA125和IL-10增高的病例数较Ⅲa期和高分化患者明显增高(P均<0.05).47例部分缓解(part re-mission,PR)患者血清CA125和IL-10水平治疗后明显降低、37例疾病进展(progressive disease,PD)患者治疗后血清CA125和IL-10水平仍明显升高、且47例PR患者生存期较37例PD患者明显延长(P均<0.05).ROC曲线分析显示:CA125和IL-10水平评估晚期NSCLC患者预后价值的AUC为0.803和0.764,临界值分别为84.1U/ml和65.2ng/L,敏感度分别为81.5%和77.4%,特异度分别为87.6%和80.1%.结论 血清CA125和IL-10水平是评估晚期NSCLC患者预后的有价值指标.%Objective To explore prognostic value to determine serum CA125 and IL-10 in patients with non-small cell lung cancer(NSCLC). Methods The serum CA125 and IL-10 levels were determined in 132 pa-tients with advanced NSCLC before and after chemo and radio therapy, and 76 patents with benign lung disease were taken as the control group. The receiver operating characteristic(ROC)curve was plotted to analyze CA125 and IL-10 as a prognostic clinical value indicator of survival. Results The serum CA125 and IL-10 levels in the study group(including 51 cases of lung adenocarcinoma, 53 cases of lung squanous carcinoma and 28 cases of adeno-squanous carcinoma)were significantly higher than those in the control group(P<0. 05~0. 001). The disease counts of ser-um CA125 and IL-10 levels in patients with Ⅳ stages and low differentiated NSCLC were significantly higher than those in patients with Ⅲa stages and high differentiated(P<0. 05). The serum CA125 and IL-10 levels decreased obviously in 47 PR patients after therapy, and significantly longer than those in 37 patients with PD(P all<0. 05). ROC curve analysis showed that the AUC were 0. 803 and 0. 764 respectively, and the cut-off points were 84. 1U/ml and 65. 2ng/L, respectively. The sensitivity were 81. 5% and 77. 4% respectively, and the specificity were 87. 6%and 80. 1% for CA125 and IL-10 as a prognostic clinical value indicator. Conclusion The serum CA125 and IL-10 can be used as independent prognostic parameters in advanced NSCLC.